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Introduction
Carcinoid tumours are neuroendocrine tumours derived primarily from enterochroma⁄n cells and may arise from any site within the body. They have been traditionally classi¢ed into tumours of foregut (stomach, bronchus, duodenum, pancreas, thymus), midgut (jejunum, ileum, ascending colon) and hindgut (transverse and distal colon and rectum) origin 1 and are known to produce a wide range of products including amines, proteins and prostaglandins. 2, 3 The synthesis of these products across the spectrum of carcinoid tumours is variable. The main biogenic amine produced, i.e. serotonin is predominantly secreted by tumours of midgut origin and only rarely by hindgut tumours. 4 Proteins including neuropeptide K and the chromogranins may be produced by all carcinoids. 2 The chromogranins (Cg) consist of at least three acidic glycoproteins (CgA, CgB, CgC) with CgA showing the widest distribution, as it is stored in the granules of all neuroendocrine tumours. 5 Some carcinoid tumours may be associated with the production of more speci¢c products, e.g. histamine, with gastric carcinoids 6, 7 and adrenocorticotropic hormone (ACTH) being associated with lung carcinoids. The a and b subunits of the hormone human chorionic gonadotropin (HCG) have also been investigated as diagnostic markers for carcinoid, 8 although their incidence is suggested to be low. Most of the products secreted by carcinoid tumours have been investigated at one time or another as potential biomarkers for this condition. The measurement of 5-hydroxyindoleacetic acid (5-HIAA), the ¢nal metabolic product of serotonin metabolism, in a 24 h urine collection, remains the most commonly used marker for carcinoid. 9 This is particularly the case where patients present with signs or symptoms of the carcinoid syndrome including diarrhoea, £ushing, wheezing or carcinoid heart disease. The percentage positivity for 5-HIAA in urine for mid, fore and hindgut tumours has been shown to be 76%, 31% and 0%, respectively. 10 The measurement of serotonin itself is technically more demanding but it has been evaluated in whole blood, in platelet-rich and in platelet-poor plasma and in urine. 4, 11 Platelet serotonin has been shown to have the highest discriminating capacity of all the indole markers 4 . More recently, we have evaluated the diagnostic potential of plasma 5-HIAA in carcinoid disease and found this to be equivalent to that of serotonin and urine 5-HIAA. 12 The main advantage of plasma 5-HIAA is that a fasting blood sample avoids the problems associated with false-positive urine 5-HIAA results owing to wellknown dietary interferences. 13 Overall, CgA has been suggested as having the best sensitivity for the diagnosis of neuroendocrine disease, 14, 15 but this limits its speci¢city for carcinoid disease. CgA is extensively metabolized and measurement of the intact molecule is suggested to be better than the measurement of fragments such as pancreostatin. 2 A range of treatment options are available for enteropancreatic neuroendocrine tumours, though most are proven only to palliate symptoms. Interferon-a 16 and the somatostatin analogues octreotide and lanreotide show signi¢cant reductions in episodes of £ushing and diarrhoea. The latter is due to decreased colonic motor dysfunction. 17 There is some evidence of objective tumour regression or stabilization with these biological therapies, but the frequency is low. Surgical resection of primary metastatic tumours, where possible, remains the only hope of long-term cure. The use of targeted radiotherapy may bring about a greater likelihood of tumour shrinkage; other targeted treatments including chemoembolization and radiofrequency ablation are also available. Systemic chemotherapy has a palliative role mainly in poorly di¡erentiated and pancreatic tumours, but responses are rare in classical slow-growing carcinoids.
Monitoring and tailoring of treatment is dependent on clinical observation, and on both biochemical and radiological investigations. The measurement of 5-HIAA in 24 h urine collections remains the most popular investigation for monitoring treatment. The concentration of CgA has been shown to correlate with tumour bulk in animal experiments 18 and may provide prognostic information. 19 However, there is very little information on the use of serotonin and plasma 5-HIAA with regard to monitoring treatment. We report on three cases to investigate the potential of using serotonin and plasma 5-HIAA in monitoring the treatment of carcinoids. Two of these patients were monitored from the start of their treatment and one participant was a carcinoid patient, already established on treatment. Some measurements of the chromogranins were also obtained during the course of monitoring these patients.
Methods
Plasma 5-HIAA and whole blood serotonin were measured using high pressure liquid chromatography with £uorescence detection as described previously. 20 Serotonin was expressed both as a concentration per litre of whole blood and in relation to the blood platelet concentration. Data were also collected to show the relationship between plasma 5-HIAA and whole blood serotonin in 143 patients' samples, of which 95 were from patients with carcinoid disease. The clinical cuto¡ values for plasma 5-HIAA and serotonin at a speci¢city of 97% were 118 nmol/L and 6.1nmol/10 9 platelets; these gave them the respective sensitivities of 89% and 77%.
Samples for plasma 5-HIAA were collected after an overnight fast by the patients. Patients were also advised to avoid serotonin-containing foods, bananas, tomatoes, plums, pineapples, walnuts for several days prior to the blood sampling. Samples for blood serotonin, although una¡ected by diet, were taken at the same time as those for plasma 5-HIAA.
CgA and CgB were measured using in-house assays at the Department of Biochemical Endocrinology, Hammersmith Hospital, London, UK. The assay for CgA used an antibody directed primarily against the pancreastatin fragment of this molecule, with a reference range of up to 60 pmol/L. The assay for CgB used an antibody directed against the GAWK fragment of this molecule, with a reference range of up to 120 pmol/L.
Results
A comparison of the relationship between plasma 5-HIAA and blood serotonin expressed to the platelet count is shown in Figure 1 . This ¢gure clearly demonstrates that the platelets become saturated with serotonin at a concentration of 50 nmol/10 9 platelets as the concentration of plasma 5-HIAA increases. The equivalent concentration of plasma 5-HIAA being 4000 nmol/L when platelets are fully saturated with serotonin.
Case 1
The patient was a 56-year-old women who presented with symptoms of abdominal pain while on holiday abroad. There was no evidence of any diarrhoea, but the patient did relate to episodes of periodic £ushing which she had attributed to oestrogen de¢ciency. A computed tomography (CT) scan of the abdomen revealed a 3 cm soft tissue mass in the mesentery and a 3 cm cystic lesion in the left adnexa. A CT-guided biopsy showed the mass to be a neuroendocrine neoplasm consistent with carcinoid. An exploratory laparotomy revealed multiple carcinoids in the bowel and the patient underwent segmental resection of the distal ileum where two carcinoids were removed. A carcinoid was also excised from the proximal ileum. A 3 cm mass in the pancreatic mesentery was not resected due to the involvement of the mesenteric blood vessels.
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Biochemical investigations on return from holiday supported a diagnosis of carcinoid disease with a serotonin of 40.1nmol/10 9 platelets and a plasma 5-HIAA of 317 nmol/L. Treatment commenced with 50 mg octreotide subcutaneously twice daily for two weeks, then converted to lanreotide (Somatuline Autogel s ) given at a dose of 60 mg monthly by deep subcutaneous injection. Symptomatic relief from £ushing occurred immediately with treatment from the start and this was paralleled by a dramatic fall in both plasma 5-HIAA and serotonin concentrations (Figure 2 ). Blood serotonin reached a concentration of 13.9 nmol/10 9 platelets after 2.5 months, and plasma 5-HIAA fell to 110 nmol/L after four months. The administration of lanreotide was increased during this period to 90 mg/ month, as episodes of £ushing began to recur after three weeks following start of treatment. The patient was also still experiencing some episodes of diarrhoea (2--3 times per day). Radiological investigations showed very little change in disease progression, but plasma 5-HIAA and blood serotonin concentrations gradually increased over a period of 16 months ( Figure 2 ) and were associated with increasing frequency of £ushing episodes. Increasing the monthly dose of lanreotide to 120 mg resulted in decline in both plasma 5-HIAA and blood serotonin concentrations with an improvement in symptoms. The patient remains clinically well with no evidence of hepatic metastases. Overall, the change in plasma 5-HIAA correlated with that of blood serotonin. The measurement of the chromogranin fragments were unfortunately not available on the ¢rst sample prior to the start of treatment due to insu⁄cient blood being taken. A slightly elevated pancreastatin (CgA) concentration was seen prior to the start of treatment with lanreotide ( Figure 3) , and levels of this marker were reduced to below the assay detection limit (o10 pmol/L) within 10 months, followed by a rise to the upper limit of the reference range at 12 months, after the start of the treatment.
Case 2
The patient was a 55-year-old man with an extensive history of diarrhoea and fatigue attributed to irritable bowel syndrome. Numerous investigations carried out over 20 years including three colonoscopies had been unhelpful. Later a magnetic resonance imaging (MRI) scan of the abdomen, abdominal ultrasound and three abdominal CT scans revealed a mesenteric desmoplastic reaction and a CT arteriogram showed features of superior mesenteric vein occlusion. An initial set of three 24 h urine collections for 5-HIAA, performed because of the onset of £ushing, were all normal. As no diagnosis could be reached, he sought an opinion at the Mayo Clinic, following which an octreoscan showed uptake in the upper abdomen medial to the right kidney and a hot spot in the neck. A further three consecutive 24 h urine collections for 5-HIAA showed moderately raised concentrations of 77, 61 and 71 mmol/day. Carcinoid was con¢rmed with a blood serotonin measurement of 32.6 nmol/10 9 platelets and plasma 5-HIAA of 195 nmol/L. An MRI scan demonstrated a 2 cm nodule in the neck, and histology showed this to be a carcinoid with a low proliferative index, consistent with the long history.
Treatment was started with octreotide 200 mg twice daily, which resulted in an immediate improvement in the patient's clinical condition and a fall in concentrations of both blood serotonin and plasma 5-HIAA ( Figure 4 ). As with Case 1, blood serotonin concentration remained permanently raised, whereas plasma 5-HIAA remained in the region just below and above the clinical cut-o¡ level (108--155 nmol/L). Only three measurements of pancreastatin (CgA) were carried out on this patient, the initial concentration being raised at 148 pmol/L, which increased to 325 pmol/L after a three-month treatment and falling to 75 pmol/L following 26 months of treatment with ocreotide (Sandostatin LAR s ) 20 mg intramuscular injection monthly. 
Case 3
The patient was an elderly man with a small bowel carcinoid and local peritoneal metastases. Clinically, he had stable disease with some diarrhoea, opening his bowels two to three times a day. Both blood serotonin and plasma 5-HIAA concentrations were very high at the start of treatment with octreotide. In fact, the platelet concentration of serotonin in this patient was at its maximum of 50 nmol/10 9 platelets. The introduction of lanreotide resulted in a fall in blood serotonin as the dose was increased to 120 mg, but overall plasma 5-HIAA concentrations rose to a peak of 1167 nmol/L at eight months after remaining stable for a period of four months ( Figure 5 ). The introduction of interferon therapy then resulted in a slight fall in the concentrations of both blood serotonin and plasma 5-HIAA. This was followed by a dramatic increase in plasma 5-HIAA to1552 nmol/L. Interestingly, the blood serotonin concentration expressed to the platelet count showed no change following interferon treatment. The introduction of interferon therapy, however, resulted in a fall in the platelet count to 182 Â10 9 /L. Expressing the serotonin to a volume of whole blood rather than to the platelet count showed a rise in serotonin, paralleling that for plasma 5-HIAA ( Figure 6 ).
The chromogranin fragments ( Figure 7) showed a wide degree of £uctuation during the course of treatment. Following treatment with lanreotide for six months, the concentration of pancreastatin (CgA) fell, whereas that of GAWK (CgB) increased. This situation reversed after the introduction of interferon. 
Discussion
For many years, the biochemical monitoring of treatment for carcinoid disease has been dependent upon the 24 h urine measurement of 5-HIAA. 21 More recently, assays for CgA have become more widely available and are being used in conjunction with 5-HIAA for monitoring treatment. Studies involving radical resection or debulking surgery or chemoembolization in patients with hepatic carcinoid metastases have shown both urine 5-HIAA and CgA, or its associated fragments, to be e¡ective therapeutic markers. 22--25 The e¡ect of somatostatin analogues on biochemical markers for carcinoid is more controversial. Kvols et al. 26 have reported a 50% decrease in 24 h urine 5-HIAA in 18 of 25 patients (72%) with metastatic carcinoid disease treated with long-acting somatostatin analogue. A larger study involving 39 patients with carcinoid syndrome, however, has shown a decrease in 24 h urinary 5-HIAA in only 18% of patients after one month of treatment with lanreotide. 27 This percentage increased to 42% following six months of treatment. Other studies have shown 37% of patients to have a 50% decrease in 24 h urinary 5-HIAA after eight months of treatment with octreotide 28 or only a slightly decreased output of 5-HIAA. 29 With regard to CgA and associated fragments, although their usefulness in diagnosis of neuroendocrine disease is well established, their accuracy in monitoring disease progression has been described as unclear. 21 In addition, there is little previous published data on the use of platelet or whole blood serotonin in monitoring the treatment of carcinoid.
The cases highlighted here do indicate the potential for 5-HIAA in plasma as a marker for following up the treatment of carcinoids. Blood serotonin, although a¡ected by saturation of the platelets, has also responded well and has paralleled the changes of plasma 5-HIAA in two of these cases. However, changes in platelet count, which can be brought about by treatment with interferon for example, may a¡ect serotonin when it is expressed in relation to the platelet count. Consequently, expressing serotonin in relation to the volume of whole blood may be better for monitoring treatment.
The measurements of the chromogranin fragments, pancreastatin (CgA) and GAWK (CgB), overall showed a much greater degree of £uctuation compared with plasma 5-HIAA and blood serotonin. Production of these fragments, however, is an in vivo process, dependent upon cleavage enzymes within the tumour tissue. Newer assays directed towards other regions of this large acidic glycoprotein are now commercially available. The relative merits of these chromogranin assays in the diagnosis and the monitoring of carcinoids have been reviewed byArdill and Erikkson. 2 Patients with carcinoid neuroendocrine tumours often survive for many years and may undergo various treatments. Thus, monitoring these patients requires clearly identi¢able biochemical markers that are measured using robust assays with good standardization and precision. Assays for the chromogranins or their fragments still lack any form of international standardization and no quality-control schemes exist for this protein. Both serotonin and 5-HIAA are clearly identi¢able chemically and can be measured by robust assays. Quality-assessment schemes exist for the measurement of 5-HIAA in urine and can easily be applied to 5-HIAA in plasma, although a scheme for blood serotonin may present more of a challenge. This small study certainly lends weight to fasting plasma 5-HIAA as a marker for monitoring the treatment of carcinoids. This is in addition to its previously described use in the diagnosis of this condition. 12 Further evaluation of plasma 5-HIAA and whole-blood serotonin in the prognosis of carcinoids requires evaluation in a larger study against other novel markers such as Neurokinin A, which has been shown to be a strong independent predictor of outcome for midgut carcinoid patients. 30 
